Lonza Error Prevention System (EPS) - Changing Human Performance in Pharmaceutical Operations.

The correctness of the secondary circuit protection plate for the on/off operation is a prerequisite for the correct action of various types of protection. In the context of the intelligence of various power system equipment, the intelligent operation and management of the secondary protection plate in substations is still a blind spot. This article designs an intelligent operation and "dual confirmation" error prevention and control system for the secondary voltage plate in substations based on machine vision artificial intelligence technology, creating a new intelligent operation mode for the secondary system, achieving on-site precise identification, error prevention interlocking, and digital intelligent verification of the on/off status of the secondary hard plate, completely eliminating problems such as false on/off, missed on/off, and effectively improving the verification efficiency of the secondary protection plate in substations to ensure the correctness of the on/off operation.

Back to table of contents Previous article Next article LettersFull AccessCultural Competence and Corporate CultureManny WertmanManny WertmanSearch for more papers by this authorPublished Online:1 Mar 2003https://doi.org/10.1176/appi.ps.54.3.403-bAboutSectionsView EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: In the December issue, Lewis A. Opler, M.D., Ph.D., reviews a videotape of a cultural competence and diversity training program. He writes, "Being oblivious to this reality [cultural factors] is fraught with as much danger as being unaware that psychotherapy is influenced by transference and countertransference or that pharmacotherapy is influenced by the cleverly crafted marketing strategies of pharmaceutical companies."The cleverly crafted marketing strategies are exquisitely depicted in the drug advertisements displayed throughout the December issue of the journal. The one that caught my eye was an advertisement for Zyprexa on the inside cover. In addition to the graphic visual message of the doctor (in a white coat) extending his arm to rescue the patient attempting to climb out of a ravine while standing on a large letter Z (color-coded throughout the ad), there is an interesting text, which, I believe is almost subliminally misleading.The narrative begins by telling us that medication isn't the only answer to the treatment of mental illness. One would think that this is a reference to additional interventions such as psychotherapy or psychosocial rehabilitation. But instead the text goes on to describe how medication can "enable a strong therapeutic alliance" with the physician to establish a "solid treatment foundation and stay on course"—presumably to facilitate the patient's compliance with medication treatment. In other words, the importance of medication as an "essential component in the treatment of mental illness" is to help the physician to treat the patient with medication!What is at issue here is not the role of pharmacological interventions in the treatment of psychiatric disorders, but, as Dr. Opler emphasizes, the need to recognize the role of cultural factors that influence psychiatric treatment—in this case corporate culture.Mr. Wertman is director of adult mental health services at the Ohel Children's Home and Family Services in Brooklyn, New York.Reference1. Opler LA: The Culture of Emotions: A Cultural Competence and Diversity Training Program. Psychiatric Services 53:1537-1538, 2002Link, Google Scholar FiguresReferencesCited byDetailsCited byNone Volume 54Issue 3 March 2003Pages 403-b-404 Metrics History Published online 1 March 2003 Published in print 1 March 2003

Introduction: Racial and ethnic minority enrollment in clinical trials is still a challenge and current recruitment planning has failed to improve diverse representation in clinical trials. The following literature review identified common barriers to diverse trial enrollment resulting in suggested tactics to address these barriers for breast cancer clinical trials. Methods: A literature review was conducted to identify barriers to oncology clinical trial enrollment for African American, Hispanic, Asian American, and Native American populations. A targeted review of barriers for patients in the lower socioeconomic status (SES) bracket was also performed. An advisory board of study coordinators was consulted to assess site–level awareness, barriers, and resources needed from the pharmaceutical industry. Additionally, ongoing initiatives were assessed including use of a Latino toolkit, patient navigators, and community outreach strategies. Results: The number of evidence based recruitment strategies targeting ethnic minorities was found to be lacking. There are four key aspects that influence diverse patients' decisions to participate in trials: family/friends, finances, faith, and physicians/staff. Barriers identified affected a majority of the analyzed patient populations. These included: protocol inclusion/exclusion criteria; logistical concerns; few incentives for participating; and cultural factors. The informed consent form and process were cumbersome and not patient-centric; costs related to travel and co-pays, and mistrust of medical research and the pharmaceutical industry were also identified as common barriers. The primary barriers were lack of invitations and lack of awareness at multiple levels within medical institutions, health care professionals, communities, and the pharmaceutical industry. Suggestions to address enrollment barriers include education to increase awareness, a patient-centric approach to consent and trial discussions, and tailoring site selection strategies. Other suggestions are immersion into communities, patient reimbursement, cultural competency training, pro-active translations, early recruitment planning, and identifying processes for approaching non-English speaking patients. Epidemiology data should also be incorporated in planning to establish baseline and enrollment goals. Conclusion: Although each of the analyzed populations is unique, common themes emerged. A patient-centric approach to increasing diversity in clinical trials should include considering a patient's key influences, addressing common concerns, conducting a properly informed consent process, and empowering a patient's decision making process. Gaps in current recruitment practices do still exist and further research on evidence based diverse recruitment strategies is also needed. Citation Format: Kelly R. Kirsch, Gebra C. Carter, Jacqueline M. Cole, Allicia C. Girvan, Coleman K. Obasaju. Recommendations to address common barriers to diversity in oncology clinical trials: An industry perspective. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr A66. doi:10.1158/1538-7755.DISP13-A66

The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?

Professor Michael J. Pikal: Scientist, family man, educator, colleague and friend

This paper aims to investigate the HRM practices and impact on Customers satisfaction in the pharmaceutical companies of Nepal A structured questionnaire was developed and distributed among 386 employees of 37 pharmaceuticals companies. Statistical correlation analysis was used to assess the impact of HRM practices on Customer satisfaction. The study reveals that employees in pharmaceutical companies are satisfied with the recruitment and selection, and training and development policy and practices of pharmaceutical companies. On the other hand, employees are dissatisfied with the human resource planning, working environment, compensation policy, performance appraisal, and industrial relations. The study suggests that the pharmaceutical companies should develop proper human resource policy and given emphasis on proper human resource practices to enhance the satisfaction of their customer and build them effective human resources.

Dear Reader, “Compliance” is a term used and practiced extensively in the Pharmaceutical Industry. None of us are strangers to compliance, such as regulatory compliance, GMP compliance, compliance to pharmacopoeial standards, SOPs and many more. There are extensive treatises and even research studies on compliance. On a routine practice, the reference to compliance is extensive. However, an equally or more important terminology is “conformance”. Pharmaceutical Industry needs to move on from legal and regulatory compliances to “conformance”.

ObjectivesIn this paper we discuss the main ethical challenges related to the conduct of medicine quality surveys and make suggestions on how to address them.MethodMost evidence‐based information regarding medicine quality derives from surveys. However, existing research ethical guidelines do not provide specific guidance for medicine quality surveys. Hence, those conducting surveys are often left wondering how to judge what counts as best practice. A list of the main ethical challenges in the design and conduct of surveys is presented.Results and conclusionsIt is vital that the design and conduct of medicine quality surveys uphold moral and ethical obligations and analyse the ethical implications and consequences of such work. These aspects include the impact on the local availability of and access to medicines; the confidentiality and privacy of the surveyors and the surveyed; questions as to whether outlet staff personnel should be told they are part of a survey; the need of ethical and regulatory approvals; and how the findings should be disseminated. Medicine quality surveys should ideally be conducted in partnership with the relevant national Medicine Regulatory Authorities. An international, but contextually sensitive, model of good ethical practice for such surveys is needed.

Artificial Intelligence (AI) is transforming pharmaceutical manufacturing by enhancing efficiency, precision, and quality. In parenteral drug manufacturing, where sterility, safety, and regulatory compliance are critical, AI plays a vital role in optimizing processes and minimizing human error. AI-driven technologies such as machine learning, computer vision, and predictive analytics support real-time monitoring of critical parameters, early detection of deviations, and automation of analytical operations. These tools improve process control in formulation, filling, sealing, and packaging while ensuring compliance with Good Manufacturing Practices (GMP). Furthermore, AI aids in predictive maintenance of equipment, advanced quality assurance, and reduced production costs. By integrating AI with robotics and continuous manufacturing systems, pharmaceutical industries can achieve higher consistency, scalability, and patient safety. Thus, AI stands as a powerful enabler in advancing the efficiency, accuracy, and reliability of parental drug manufacturing.

Health is one of the most important aspects of human life. For a healthy society, the healthcare sector must be reliable and efficient as much as possible. Blockchain networks can be used to provide innovative solutions to store and share patient data among hospitals, pharmaceutical companies, diagnostic labs, and physicians. Blockchain applications are capable of building trust and detecting fatal errors in the sharing of data. So blockchain can help in the security, effectiveness, and transparency of sharing medical data in the healthcare industry. Using this technology, medical institutions can get quality and trustworthy knowledge which they can use to improve the analysis of patient data and help in the good diagnosis of health issues. A thorough study and analysis have been done to explore the opportunities that blockchain technology can provide to improve the healthcare industry. The various characteristics, methods, and smooth workflow processes of blockchain technology are discussed in diagrams as a potential means of improving global healthcare. The article concludes by listing and analyzing various significant blockchain applications for the healthcare industry. It can help in implementing the smart contract, nonce concepts, and P2P distributed ledgers which ensure the immutability of the shared data. The methods discussed in this paper improve the security of Electronic Health Records (EHRs). The data of patients are taken directly via IoT devices which are used as medical instruments for patients which increases the reliability of data as there is no human interference in between hence human error is eliminated. The proposed technique implementation results show that the security of data has increased and it is more efficient.

European Paediatric Formulation Initiative workshop report: Improving the administration of oral liquid medicines in paediatrics using dosing syringes and enteral accessories

This article provides an overview on the Institute for Safe Medication Practices (ISMP), the only independent nonprofit organization in the USA devoted to the prevention of medication errors. ISMP developed the national Medication Errors Reporting Program (MERP) and investigates and analyzes errors in order to formulate recommendations to prevent further occurrences. ISMP works closely with the US Food and Drug Administration (FDA), drug manufacturers, professional organizations, and others to promote changes in package design, practice standards, and healthcare practitioner and consumer education. By collaborating with ISMP to share and disseminate information, Poison Control centers, emergency departments, and toxicologists can help decrease unintentional and accidental poisonings.

The utilization of various herbals in the different traditional therapeutical and medicinal systems has been reported prehistorically. India due to its geographical positioning on the global map is blessed with a variety of climatic and growth conditions and sustains various herbals. India is the largest producer of medicinal plants and herbs and is also referred to as a ‘botanical garden of the world’. The use of herbals as functional and neutraceutical food ingredients is not a new concept and is known for centuries and nearly 80% of the world's population still rely on herbals or their processed products for different therapeutic applications. Murraya koenigii l. (meethi neem) is well recognized for its unique flavor and is used in various cuisines as fresh leaves or spice mix as powder. The therapeutic potential of Murraya leaf is well reported in conditions like diabetes, diarrhoea, cancer, HIV, ulcer, obesity, inflammation and skin related problems. Also, the potent antimicrobial activity of the shrub expands its application as extract, powder or nanoparticles to cosmetic and pharmaceutical industry. Continuous efforts are underway to explore the nutraceutical properties of the plant to boost its utilization in various food applications. Production of powder and extract from fresh leaves, fruits, seeds and roots, however, results in losses of bioactives and phyto-nutrients. Hence, the research personals and industries are evolving continuously for exploring alternative methods like freeze-drying, microwave and ultrasound-assisted dehydration, vacuum dehydration, etc. to minimize such losses. Murraya based nanoparticles for improving the delivery of target compounds have gained significant attention. The present review has been compiled to provide an insight into the fresh use and value addition of the herb with its potential therapeutic and medicinal properties along with the developments made in the field of processing, extraction and concerned health benefits.

Article history: Received January 20, 2014 Accepted 5 July 2014 Available online August 25 2014 In order to improve the organizational performance, strategies in the human resources are among the elements taken into consideration. On this basis, the present research is aimed at studying the role of human resources strategies in the organizational performance of Barij Essence Kashan Pharmaceutical Company. In terms of goal, the present research is descriptivecorrelative and in terms of data collection, the survey method has been used. The main means of research data collection has been questionnaires and the validity and consistency tests have been carried out on the questionnaires. The statistical population is consisted of managers, directors, and experts of the Barij Essence Kashan Pharmaceutical Company during the winter of 2013-2014. Simple random sampling method has been used in the research and the number of people in the statistical population is 48. In research data collection, both library and field (questionnaire) methods have been used. The Pearson correlation coefficient and the multivariate regression have been employed in analysis of the data. By verifying the examined hypothesis, the findings of the research reveal that the human resources strategies generally influence on the organizational performance in five groups of absorption and employment strategy, human resources development strategy, performance management strategy, service compensation strategy, and employees’ relations strategy. © 2014 Growing Science Ltd. All rights reserved. Stock liquidity Strategy Human resources management Organizational performance Barij Essence Pharmaceuticals

Aiming at the problems of wrong brand, mixed batch and wrong transmission of electronic parameter information in the production of cut tobacco of different brands in the tobacco industry, a fully intelligent quality error prevention system based on WinCC configuration software and PLC distributed control program is designed. The information of the production and manufacturing execution system in the general control room and the brand, batch and other information stored in the PLC of the bottom electric control cabinet is compared and verified instead of manual self-inspection. If the information is consistent, production is allowed. Otherwise, the equipment locks itself and sends alarm feedback. The design and application of the system realize the automatic error prevention of process equipment and the implementation accuracy of production control parameters, to ensure that the production process meets the requirements of process technology, effectively avoid major quality accidents, and finally guarantee the product quality.